InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23 tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
TEL AVIV, Israel and MIAMI, Nov. 01, 2023 InspireMD, Inc. , developer of the CGuard™ Embolic Prevention Stent System for the prevention of stroke, today presented 30-day results from the.
InspireMD (NSPR) Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. IDE Clinical Trial at VIVA23 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Results from five clinical trials were presented during the VIVA (Vascular InterVentional Advances) Conference, VIVA23, providing outcomes from studies on treatment for chronic limb-threatening ischemia (CLTI), use of drug-coated balloons, among other highly-anticipated late-breaking science findings.
Third Round of Late-Breaking Clinical Trial Results Announced at VIVA23 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.